Switch theme
Sign up to access all valuation multiples
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
n/a
LTM Revenue $3.7M
LTM EBITDA -$30.7M
$85.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Maat Pharma has a last 12-month revenue of $3.7M and a last 12-month EBITDA of -$30.7M.
In the most recent fiscal year, Maat Pharma achieved revenue of $2.4M and an EBITDA of -$19.8M.
Maat Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Maat Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.5M | $2.4M | XXX | XXX | XXX |
| Gross Profit | $0.9M | $1.2M | XXX | XXX | XXX |
| Gross Margin | 56% | 49% | XXX | XXX | XXX |
| EBITDA | -$14.1M | -$19.8M | XXX | XXX | XXX |
| EBITDA Margin | -916% | -828% | XXX | XXX | XXX |
| Net Profit | -$9.7M | -$14.7M | XXX | XXX | XXX |
| Net Margin | -631% | -615% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Maat Pharma's stock price is EUR 6 (or $6).
Maat Pharma has current market cap of EUR 94.9M (or $102M), and EV of EUR 80.0M (or $85.9M).
See Maat Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $85.9M | $102M | XXX | XXX | XXX | XXX | $-2.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Maat Pharma has market cap of $102M and EV of $85.9M.
Maat Pharma's trades at 23.2x LTM EV/Revenue multiple, and -2.8x LTM EBITDA.
Analysts estimate Maat Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Maat Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $85.9M | XXX | XXX | XXX |
| EV/Revenue | 35.9x | XXX | XXX | XXX |
| EV/EBITDA | -4.3x | XXX | XXX | XXX |
| P/E | -4.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMaat Pharma's NTM/LTM revenue growth is 167%
Maat Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Maat Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Maat Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Maat Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 56% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -828% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 41% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -661% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 115% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 943% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 969% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Maat Pharma acquired XXX companies to date.
Last acquisition by Maat Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Maat Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| Where is Maat Pharma headquartered? | Maat Pharma is headquartered in France. |
| Is Maat Pharma publicy listed? | Yes, Maat Pharma is a public company listed on PAR. |
| What is the stock symbol of Maat Pharma? | Maat Pharma trades under MAAT ticker. |
| When did Maat Pharma go public? | Maat Pharma went public in 2021. |
| Who are competitors of Maat Pharma? | Similar companies to Maat Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Maat Pharma? | Maat Pharma's current market cap is $102M |
| What is the current revenue of Maat Pharma? | Maat Pharma's last 12-month revenue is $3.7M. |
| What is the current EBITDA of Maat Pharma? | Maat Pharma's last 12-month EBITDA is -$30.7M. |
| What is the current EV/Revenue multiple of Maat Pharma? | Current revenue multiple of Maat Pharma is 23.2x. |
| What is the current EV/EBITDA multiple of Maat Pharma? | Current EBITDA multiple of Maat Pharma is -2.8x. |
| What is the current revenue growth of Maat Pharma? | Maat Pharma revenue growth between 2023 and 2024 was 56%. |
| Is Maat Pharma profitable? | Yes, Maat Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
